Ketorolac use in outpatients and gastrointestinal hospitalization: A comparison with other non-steroidal anti-inflammatory drugs in Italy

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 393-397

  Menniti Ippolito, F ^a   Maggini, M ^a   Raschetti, R ^a   Da Cas, R ^a   Traversa, G ^a   Walker, A M ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse drug reaction; Ketorolac; NSAIDs

Indexed keywords

DICLOFENAC; KETOPROFEN; KETOROLAC; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; DATA BASE; DIGESTIVE SYSTEM PERFORATION; ENDOSCOPY; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; STATISTICS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; KETOROLAC; MALE; MIDDLE AGED; OUTPATIENTS; PEPTIC ULCER; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS; TOLMETIN;

EID: 0031875469     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050481     Document Type: Article

References (10)

1. Italian Ministry of Health (1995) Farmacovigilanza-Ketorolac Ministero della Sanitá, Bollettino d'informazione sui farmaci 1: 4-5
2. Anonymous (1993) Ketorolac: restrictions on parenteral dosage. WHO Drug Info: 64
3. Gillis JC, Brogden RN (1997) Ketorolac - a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 53: 139-188
4. Traversa G, Walker AM, Menniti-Ippolito F, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Spila Alegiani S, Raschetti R (1994) Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology 6: 49-54
5. Anonymous (1985) Nordic statistics on medicines 1981-1983, part II: Nordic Drug index with classification of defined daily doses (in Swedish). Uppsala, NLN publication No. 15
6. Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6: 356-365
7. Anonymous (1993) EGRET. Washington Statistics and Epidemiology Research Corporation, Seattle
8. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. Ann Intern Med 115: 787-796
9. Bollini P, García Rodríguez LA, Pérez Gutthann S, Walker AM (1992) The impact of research quality and study design of epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 152: 1289-1295
10. Henry D, L-Y Lim L, García Rodríguez LA, Pérez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT (1996) Variability in risk of gastrointestinal complications with individual non-steroidal antiinflammatory drugs: results of a collaborative meta-analysis. BMJ 312: 1563-1566